Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 1
1984 1
1985 2
1988 1
1989 1
1990 1
1991 2
1995 1
1996 1
2000 1
2001 2
2006 1
2007 1
2008 1
2009 4
2010 2
2011 1
2012 3
2013 2
2014 2
2015 3
2016 4
2017 5
2018 2
2019 2
2020 5
2021 6
2022 5
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
2023 ESC Guidelines for the management of cardiomyopathies.
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. Arbelo E, et al. Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194. Eur Heart J. 2023. PMID: 37622657 No abstract available.
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Kittleson MM, et al. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Circulation. 2020. PMID: 32476490 Free article. Review.
Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Enthus …
Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular depositi …
Cardiac Amyloidosis Treatment.
Stern LK, Patel J. Stern LK, et al. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):59-72. doi: 10.14797/mdcvj.1050. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 35414852 Free PMC article. Review.
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen sign …
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment opt …
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Siddiqi OK, Ruberg FL. Siddiqi OK, et al. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13. Trends Cardiovasc Med. 2018. PMID: 28739313 Free PMC article. Review.
Treatment is aimed at relieving congestive symptoms and targeting the underlying amyloidogenic process. This includes anti-plasma cell therapy in AL amyloidosis, and stabilization of the TTR tetramer or inhibition of TTR protein production in ATTR amyloidosis. Cardiac tran …
Treatment is aimed at relieving congestive symptoms and targeting the underlying amyloidogenic process. This includes anti-plasma cell th …
Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association.
Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, Feingold B, Lal AK, Lee TM, Canter CE, Lipshultz SE; American Heart Association Young Hearts Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts). Bogle C, et al. Circulation. 2023 Jul 11;148(2):174-195. doi: 10.1161/CIR.0000000000001151. Epub 2023 Jun 8. Circulation. 2023. PMID: 37288568 Review.
Other less frequent cardiomyopathies, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic cardiomyopathy, are discussed in less detail. ...These differences will likely affect the utility of some adult therapy strat …
Other less frequent cardiomyopathies, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic …
State-of-the-art document on optimal contemporary management of cardiomyopathies.
Seferović PM, Polovina M, Rosano G, Bozkurt B, Metra M, Heymans S, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Olivotto I, Rapezzi C, Linhart A, Corrado D, Tschöpe C, Milinković I, Bayes Genis A, Filippatos G, Keren A, Ašanin M, Krljanac G, Maksimović R, Skouri H, Ben Gal T, Moura B, Volterrani M, Abdelhamid M, Lopatin Y, Chioncel O, Coats AJS. Seferović PM, et al. Eur J Heart Fail. 2023 Nov;25(11):1899-1922. doi: 10.1002/ejhf.2979. Epub 2023 Sep 24. Eur J Heart Fail. 2023. PMID: 37470300 Review.
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical …
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-b …
Clinical management of amyloid cardiomyopathy.
Kim MM, Kolseth CM, Carlson D, Masri A. Kim MM, et al. Heart Fail Rev. 2022 Sep;27(5):1549-1557. doi: 10.1007/s10741-021-10159-w. Epub 2021 Sep 1. Heart Fail Rev. 2022. PMID: 34471997 Review.
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical manag …
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In …
Diagnosis and Management of Endomyocardial Fibrosis.
Beaton A, Mocumbi AO. Beaton A, et al. Cardiol Clin. 2017 Feb;35(1):87-98. doi: 10.1016/j.ccl.2016.08.005. Cardiol Clin. 2017. PMID: 27886792 Review.
Endomyocardial fibrosis (EMF) remains an important cause of restrictive cardiomyopathy worldwide. Patients cluster in specific geographic locations and are almost universally living in extreme poverty. ...Increased awareness, advocacy, and research are needed to fur …
Endomyocardial fibrosis (EMF) remains an important cause of restrictive cardiomyopathy worldwide. Patients cluster in specific …
Genetic profile and genotype-phenotype correlations in childhood cardiomyopathy.
Wanert C, El Louali F, Al Dybiat S, Nguyen K, Zaffran S, Ovaert C. Wanert C, et al. Arch Cardiovasc Dis. 2023 Jun-Jul;116(6-7):309-315. doi: 10.1016/j.acvd.2023.04.008. Epub 2023 May 16. Arch Cardiovasc Dis. 2023. PMID: 37246080
METHODS: We performed a retrospective study of all patients with idiopathic cardiomyopathy aged<18years in Southeast France. Secondary causes of cardiomyopathy were excluded. All data (clinical, echocardiography, genetic testing) were collected retrospectively. P …
METHODS: We performed a retrospective study of all patients with idiopathic cardiomyopathy aged<18years in Southeast France. Secon …
Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies.
Polovina M, Tschöpe C, Rosano G, Metra M, Crea F, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Corrado D, Bayes-Genis A, Bozkurt B, Filippatos G, Keren A, Skouri H, Moura B, Volterrani M, Abdelhamid M, Ašanin M, Krljanac G, Tomić M, Savarese G, Adamo M, Lopatin Y, Chioncel O, Coats AJS, Seferović PM. Polovina M, et al. Eur J Heart Fail. 2023 Dec;25(12):2144-2163. doi: 10.1002/ejhf.3076. Epub 2023 Nov 14. Eur J Heart Fail. 2023. PMID: 37905371 Review.
It occurs at a rate ranging between 0.15% and 0.7% per year (depending on the cardiomyopathy), which significantly surpasses SCD incidence in the age- and sex-matched general population. ...In this review, we aim to provide an in-depth discussion of the contemporary concep …
It occurs at a rate ranging between 0.15% and 0.7% per year (depending on the cardiomyopathy), which significantly surpasses SCD inci …
66 results